UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients

Pharmacogenomics. 2012 Jun;13(8):879-88. doi: 10.2217/pgs.12.69.

Abstract

Aim: To test whether the genetic polymorphisms within the gene encoding the UGT2B7 gene may have an impact on methadone treatment.

Materials & methods: Twelve SNPs in UGT2B7 were selected. 366 methadone maintenance treatment patients in Taiwan were recruited and genotyped.

Results: In a genotype recessive model, rs6600879, rs6600880, rs4554144, rs11940316, rs7438135, rs7662029, rs7668258, rs7439366, rs4292394 and rs6600893 showed significant associations with severity of withdrawal symptoms (permutation p < 0.002), pupil size (permutation p < 0.048) and tremor (permutation p < 0.008). Haplotypes of GATCAGCCGC and CTCTGATTCT were significantly associated with pupil size score and tremor score (p < 0.034).

Conclusion: These results suggest that SNPs of the UGT2B7 gene may play important roles in opiate withdrawal symptoms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amitriptyline / blood
  • Female
  • Genetic Association Studies
  • Glucuronosyltransferase / genetics*
  • Haplotypes
  • Heroin Dependence / drug therapy
  • Heroin Dependence / genetics
  • Humans
  • Linkage Disequilibrium
  • Male
  • Methadone* / administration & dosage
  • Methadone* / adverse effects
  • Methadone* / blood
  • Middle Aged
  • Morphine* / blood
  • Morphine* / urine
  • Polymorphism, Single Nucleotide
  • Pyrrolidines / blood
  • Substance Withdrawal Syndrome / genetics*
  • Substance Withdrawal Syndrome / pathology
  • Taiwan

Substances

  • Pyrrolidines
  • Amitriptyline
  • Morphine
  • UGT2B7 protein, human
  • Glucuronosyltransferase
  • Methadone
  • 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine